TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome.

doi:10.1016/j.bcmd.2016.05.007

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome.

Blood cells, molecules & diseases - 1 Jul 2016

Weich Natalia, Ferri Cristian, Moiraghi Beatriz, Bengió Raquel, Giere Isabel, Pavlovsky Carolina, Larripa Irene, Fundia Ariela

Abstract excerpt

BCR-ABL1 gene is a key molecular marker of chronic myeloid leukemia (CML), but it is still unclear which molecular factors may influence CML risk or lead to variable responses to tyrosine kinase inhibitors (TKIs). The aim of this study was to investigate the impact of TP53 c.213 G>C(Arg72Pro; rs1042522) polymorphism on CML risk and its correlation with clinical outcome. Peripheral blood samples from 141 treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Codon

Share to Disease-Free Survival

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Treatment Failure

Share to Treatment Outcome

Share to Tumor Suppressor Protein p53

Source

Open in PubMed

Identifiers

PMID: 27282582
DOI: 10.1016/j.bcmd.2016.05.007

Genes

ABL1
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome.PMID 27282582Read ↗

Arginine homozygosity in codon 72 of p53 correlates with failure to imatinib response in chronic myeloid leukemia.Semantic proximity Read ↗

The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Systematic Review and Meta-Analysis.Semantic proximity Read ↗

The relationship between leukemia and TP53 gene codon Arg72Pro polymorphism: analysis in a multi-ethnic population.Semantic proximity Read ↗

Association Between TP53 Gene Codon 72 Polymorphism and Acute Myeloid Leukemia Susceptibility: Evidence Based on a Meta-Analysis.Semantic proximity Read ↗

MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.Semantic proximity Read ↗

p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis.Semantic proximity Read ↗

Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia.Semantic proximity Read ↗

TP53 Gene 72 Arg/Pro (rs1042522) single nucleotide polymorphism increases the risk and the severity of chronic lymphocytic leukemiaSemantic proximity Read ↗

TP53 Codon 72 Polymorphism and Risk of Acute LeukemiaSemantic proximity Read ↗

MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: an Egyptian study.Semantic proximity Read ↗

Association between TP53 Arg72Pro polymorphism and leukemia risk: a meta-analysis of 14 case-control studies.Semantic proximity Read ↗

Role of p53 Codon72 SNP in breast cancer risk and anthracycline resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.